Xeloda - Newsfeeds

Battling Jo vows to fulfil a dream: Clinical data submitted by the manufacturer shows it can typically offer patients an extra six weeks of life when added to chemotherapy drugs capecitabine and oxaliplatin.
Genentech gets Refuse to File letter for T-DM1 BLA: Genentech's Emilia study is a comparative study between T-DM1 and Lapatinib in combination with capecitabine in people with advanced HER2-positive breast cancer whose disease has worsened after receiving initial ...
Genentech Updates Status of FDA Application for T-DM1: The EMILIA study compares T-DM1 to lapatinib in combination with capecitabine in people with advanced HER2-positive breast cancer whose disease has worsened after receiving initial treatment. T-DM1 is an antibody ...
FDA kicks breast cancer drug back to Genentech: which will compare the armed antibody to lapatinib in combination with capecitabine in women whose breast cancer has worsened after initial treatment. Genentech expects to submit a new application in mid-2012. “
Ways in which fingerprints can fade: As reported by the "Annals of Oncology," the chemotherapy drug he was taking - capecitabine - had caused swelling and peeling of his palms and soles. Released when officials decided he was no security risk, "
Today in the press: the Xeloda intermediate, methyl furanoside. The company said it plans to begin manufacturing this product in the first half of 2010.
New cancer drugs funded: and the oral drug capecitabine (Xeloda) for colon and rectal cancer. A fourth drug, mycophenolate (Cellcept), is also included in the deal. Pharmac says the immunosuppressant used in transplantation and some auto ...
A Look at Immunogen Beyond the T-DM1 Setback: the drug has a decent shot to beat the control arm (Tykerb+Xeloda). T-DM1’s potential market remains unchanged, with a blockbuster potential based on the $4.8B in sales Herceptin had last year. Herceptin’s sales ...
Adjuvant Chemo Drugs Equal for Pancreatic Cancer: Their ESPAC-4 study is under way to compare the addition of capecitabine (Xeloda) to gemcitabine alone. The study was supported by Cancer Research UK; National Cancer Institute of Canada, Canadian Cancer Society;
Aeterna Zentaris (AEZS) Reports Final Results of Phase 2 Study of Perifosine in the Treatment of ...: ... activation in the phosphoinositide 3-kinase (PI3K) pathway, in combination with capecitabine (Xeloda(R)) as a treatment for advanced, metastatic colorectal cancer. Abstract #3531, entitled, "Final results of a ...

Aeterna Zentaris, Keryx Says Cancer Drug Perifosine Meets Phase 2 Trial Goals - Update: KERX: News ), Tuesday said the phase 2 study of its novel, oral anticancer agent, perifosine or KRX-0401, in combination with capecitabine or Xeloda versus capecitabine, in patients with second- or third-line metastatic ...
Nektar's Drug Holds Strong Potential: About 85% of the 70 patients enrolled in the trial received treatment with anthracycline/taxane and with or without capecitabine. It was observed that 21% of the evaluable patients (14/66) responded to treatment with ...
Aeterna Zentaris (AEZS) Reports Final Results of Phase 2 Study on Perifosine for Treatment of ...: ... 11 centers across the United States, heavily pre-treated patients with second- or third-line metastatic colorectal cancer were randomized to receive capecitabine (a chemotherapy used in advanced metastatic ...
Thousands of breast cancer patients 'to be denied life-prolonging drug': Around 2,000 women a year in Britain would be eligible for the drug, which is used in combination with a chemotherapy treatment called capecitabine. Nice said that it was “disappointed” not to be able to recommend ...
NICE Rules Against NHS Funding For Tyverb (Lapatinib), An Effective Treatment For Advanced Breast ...: ... and Clinical Excellence (NICE) issued its Final Appraisal Determination (FAD) advising against NHS funding for oral Tyverb (lapatinib) in combination with Xeloda® (capecitabine) for the treatment of an aggressive ...
Glaxo cancer drug rejected for UK state funding: The agency's final draft guidance follows preliminary rebuffs for the Glaxo product, which is designed for use in combination with Roche's pill Xeloda to treat an aggressive form of advanced breast cancer.
Keryx Announces Final Results Of Mid Stage Study Of Colorectal Cancer Drug KRX-0401 - Quick Facts: ... results of the mid stage study on the clinical activity of KRX-0401 or perifosine, the company's oral anti-cancer agent, in combination with capecitabine or Xeloda as a treatment for advanced, metastatic colorectal ...
NICE rejects breast cancer drug: Tyverb is a pill used in combination with the chemotherapy Xeloda (capecitabine) for women with hormone sensitive advanced breast cancer. It is a last resort for those whose treatment with standard chemotherapies and ...
New Breakthroughs in Cancer Treatment: Oral Chemotherapy Better Than Intravenous Chemotherapy for Colon Cancer A study has been released proving that taking an oral chemotherapy drug called Xeloda for colon cancer is more effective than traditional ...
Keryx Presents Encouraging Data: The randomized, double-blind, placebo-controlled study compared perifosine plus capecitabine (Xeloda) with placebo plus capecitabine in patients with refractory advanced colorectal cancer. The final results from the ...

Want to contact a Xeloda lawyer in Washington, DC? ...Get a free case evaluation from one of our Xeloda lawyers in Washington, DC now.

Content provided by MSN. LegalView is not responsible for the accuracy of the information provided above.

Pages: 1 2 3 Next

Need A Xeloda Attorney?

First Name Last Name Email Address State

Legal Issue

DrugWatch: Xeloda Click to select a Legal Issue

Has Your Health Been Negatively Affected?

Please Describe the Injury

close this window

Xeloda Information

Click to View Our Legal Resources

Want to contact a Xeloda lawyer in Washington, DC? ...Get a free case evaluation from one of our Xeloda lawyers in Washington, DC now.

LegalView.info is sponsored by law firms with offices in many states. This website contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Your access to this site does not constitute a legal attorney-client relationship. The choice of a lawyer is an important decision and should not be based solely upon advertisements. To access important information concerning the sponsors and their commitment to the ethical practice of law, click here.

The participating law firms are as follows: Anapol Schwartz (Philadelphia, Pennsylvania; Cherry Hill, New Jersey; Media, Pennsylvania; Reading, Pennsylvania; Wheeling, WV). Cohen, Placitella & Roth (Red Bank, New Jersey; Philadelphia, Pennsylvania). J. F. Humphreys (Charleston, West Virginia). Lopez McHugh (Newport Beach, California; Philadelphia, PA; and Moorestown, NJ). Click here for more information about these law firms.

Some of our partner firms do not accept some types of cases. For details on these case exceptions, click here.

20120223-061707

Close (x)

Looking for an Attorney?

Please type your question:

First Name:
Last Name:
E-mail:
Phone Number *
() -

State * Legal Issue *

DrugWatch: Xeloda Click to select a Legal Issue

Close (x)

Find Legal Help for Your Xeloda Case - Submit Your Information Below

Do you need legal assistance with your Xeloda case?
LegalView may be able to help.

Submit your information below for a free, no-cost evaluation.

We'll submit your information to one of our partner firms.
LegalView's partners represent clients throughout the United States, for a very wide range of legal issues. Submit your information now, to see if one of LegalView's partners can help!

* Indicates Required Fields

First name *

Last name *

Email Address *

Phone Number *
() -

State *

Legal Issue * DrugWatch: Xeloda Change

Was There an Injury?

Please Describe The Injury

Please State Your Question *

DISCLAIMER and STATEMENT OF NON-CONFIDENTIALITY

By submitting this form, you agree that completing the above is not intended to create an attorney-client relationship.

Disclosure

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website, LegalWebMedia.com will submit your information to the law firms that pay for this group advertising and to respond to your requests for information concerning legal services in their assigned local areas. If there is no sponsoring firm in your state, your inquiry will be submitted to one of the sponsoring law firms on a predetermined, rotating basis. If the sponsoring law firm accepts your case, it will associate with licensed attorneys practicing in your state, if required; the sponsoring law firm may also contact other law firms to see if they may be able to assist.

The information provided by the LegalView.com and LegalWebMedia.com websites is for advertising and informational purposes and should not be considered as legal advice from the sponsoring attorneys. The websites contain general information and may not reflect current legal developments, verdicts, or settlements. LegalView.com contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Any person viewing or receiving information from these websites should not act or refrain from acting on the basis of any such information without first seeking appropriate legal advice from an attorney in your area. Legal WebTV Network, LLC expressly disclaims any liability with respect to actions taken or not taken by the recipient based on any or all of the information or contents contained in these websites.

Any information sent to Legal WebTV Network LLC through this website is done using standard Web encryption techology. LegalView.com will exercise all reasonable care, within technological limits, to protect the confidentiality of any information submitted via Internet e-mail or through this website. By accessing this website, you may be seeking an attorney to represent you or legal advice. However, none of the sponsoring attorneys represent you yet.

The choice of a lawyer is an important decision and should not be based solely upon advertisements.

Any transmission of information, whether via Internet e-mail or through the website, is solely for evaluation purposes by the sponsoring law firms and their associates. The transmission of any information to any attorney sponsoring advertising on LegalView.com or LegalWebMedia.com does not create an attorney-client relationship between the sender and any recipient. An attorney-client relationship can only be created by a written, signed-fee agreement entered into with an attorney. The sponsoring attorneys will treat your information as a confidential communication for the purpose of obtaining legal services or legal advice.

For more information about the sponsoring law firms, please click here.

This form is secure and encrypted. More information about secure forms and your privacy here.